5 Latest Stock Picks of Billionaire Ray Dalio

3. Moderna, Inc. (NASDAQ:MRNA)

Bridgewater Associates’ Stake Value: $3,198,000
Percent of Bridgewater Associates’ 13F Portfolio: 0.01%
Number of Hedge Fund Holders: 37

Moderna, Inc. (NASDAQ:MRNA), an American biotech company, recently got FDA’s approval to widen Covid-19 booster eligibility for all adults, aged 18 years and above. As of Q3, the company represents 0.01% of Ray Dalio’s portfolio.

At the end of Q2 2021, 37 hedge funds in Insider Monkey’s database reported owning stakes in Moderna, Inc. (NASDAQ:MRNA), compared with 39 in the previous quarter. The total value of these stakes is over $5.7 billion, up significantly from $1.6 billion as recorded in the previous quarter.

Recently, Piper Sandler reiterated an Overweight rating on Moderna, Inc. (NASDAQ:MRNA), while keeping a $348 price target on the stock, after the company presented a successful trial of its medicine for solid tumors and lymphoma. In its Q3 earnings, Moderna, Inc. (NASDAQ:MRNA) presented a striking 3,047.4% year-over-year growth in revenue at $4.97 billion.

Carillon Tower Advisers mentioned Moderna, Inc. (NASDAQ:MRNA) in its recently published Q3 2021 investor letter. Here is what the firm has to say:

“Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The stock proved to be an impressive contributor once again in the quarter, as investors continue to evaluate the potential for future growth driven primarily by the firm’s revolutionary COVID-19 vaccine. Strong global demand for the vaccine may persist for the foreseeable future in order to maintain immunity as well as provide protection against any additional future variants. The potential for the firm’s mRNA technology to be used in a number of other use cases, specifically influenza, could also provide an additional tailwind for future growth.”